Skip to main content
Clinical Trials/NCT07460882
NCT07460882
Not yet recruiting
Not Applicable

The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertension

Johns Hopkins University0 sites607 target enrollmentStarted: May 1, 2026Last updated:

Overview

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
607
Primary Endpoint
Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L)

Overview

Brief Summary

The goal of this pre-post study is to assess the risk of hyperkalemia in adults with hypertension on medication in Bangladesh. The main questions it aims to answer are:

Is the risk of hyperkalemia after the initiation of Low Sodium Salt Substitute (LSSS) in people on antihypertensive medication (especially RASi) large enough to be concerned about its broad use in this population?

Does initiation of LSSS correct hypokalemia in people on antihypertensive medication (especially RASi) with low serum potassium levels?

Participants will be asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adults ≥18 years with clinically diagnosed hypertension treated with medication \[on a stable dose at least for 2 months\]
  • Have a phone for contact

Exclusion Criteria

  • Those with baseline K ≥5.0 or K \<3.0 mmol/L
  • Advanced kidney disease (eGFR \<45 ml/min/1.73m2).
  • Those on potassium sparing diuretics (e.g., spironolactone)
  • Other medical conditions determined by physicians (e.g., heart failure treated with medication; life expectancy less than 12 months)
  • Dine out for dinner more than 3 times a week

Arms & Interventions

Low sodium salt substitute (LSSS)

Experimental

Participants are asked to reduce overall salt intake and to use LSSS on every occasion where regular salt would normally be used, including as cooking salt

Intervention: Low-sodium salt substitute (Dietary Supplement)

Outcomes

Primary Outcomes

Proportion of the correction of hypokalemia (from K <3.5 mmol/L to 3.5-5.0 mmol/L)

Time Frame: 4 and 8 weeks

Incident hyperkalemia (K ≥5.5 mmol/L)

Time Frame: 4 and 8 weeks

Secondary Outcomes

  • Change in serum potassium levels(4 and 8 weeks)
  • Change in systolic and diastolic blood pressure (mmHg)(4 and 8 weeks)
  • Number of Participants Adherent to LSSS use(4 and 8 weeks)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Similar Trials